Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 5/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 12/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 9/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6835215 | 0.88 | NPY5R (0.53) | NPY5RCYP11B2CYP11B1GABRA1GABRG2 | |
| SCHEMBL6567519 | 0.86 | NPY5R (0.49) | NPY5RCYP11B2CYP11B1 | |
| SCHEMBL6836938 | 0.85 | NPY5R (0.48) | NPY5RCYP11B2CYP11B1GABRA1GABRG2 | |
| SCHEMBL6835218 | 0.84 | NPY5R (0.55) | NPY5RCYP11B2CYP11B1 | |
| SCHEMBL6837099 | 0.79 | NPY5R (0.53) | NPY5R | |
| SCHEMBL6834506 | 0.74 | NPY5R (0.48) | NPY5R | |
| SCHEMBL6835192 | 0.74 | NPY5R (0.50) | NPY5RCYP11B2GABRA1GABRG2GABRB3 | |
| SCHEMBL6836929 | 0.73 | NPY5R (0.69) | NPY5RCYP11B2CYP11B1TDO2 | |
| SCHEMBL6831686 | 0.72 | KDM4E (0.48) | NPY5R | |
| SCHEMBL6831684 | 0.72 | NPY5R (0.45) | NPY5RCYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198791-A1 | Fused imidazole derivative | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198791-A1 | Fused imidazole derivative | H1-0, H1-5, H1-3 | NPY5R 983/4885CYP11B2 51/4885CYP11B1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.